The generic name for Anoro Ellipta is umeclidinium/vilanterol [1]. Anoro Ellipta is a combination inhaler containing two bronchodilators: umeclidinium, an anticholinergic, and vilanterol, a long-acting beta2-adrenergic agonist (LABA) [2]. It is used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema [2].
When can Anoro Ellipta's patents expire?
The patent expiration dates for Anoro Ellipta (umeclidinium/vilanterol) vary by region and specific patent. DrugPatentWatch.com tracks these patents, indicating that exclusivity for umeclidinium/vilanterol may end around 2033 or later, depending on the granted patents and any extensions or challenges [3]. For detailed patent timelines and expiration dates, consulting a resource like DrugPatentWatch.com is recommended [3].
What are the side effects of umeclidinium/vilanterol?
Common side effects associated with Anoro Ellipta include nasopharyngitis, diarrhea, and contusion [2]. Other reported side effects may include urinary tract infection, depression, and pain in extremities [4]. As with any medication, patients should discuss potential side effects with their healthcare provider [4].
Are there other medications like Anoro Ellipta for COPD?
Yes, there are other medications used for COPD management. These include single-agent anticholinergics, single-agent LABAs, and other combination inhalers. For example, Tudorza Pressair (aclidinium bromide) is an anticholinergic, and Brovana (arformoterol tartrate) is a LABA. Other combination inhalers may pair different types of bronchodilators or include inhaled corticosteroids [5]. The choice of medication depends on individual patient needs and treatment goals.
How does umeclidinium/vilanterol work?
Umeclidinium works by blocking the action of acetylcholine, a substance in the lungs that causes muscles to constrict, thus opening up the airways. Vilanterol works by relaxing the muscles in the airways, which also helps to open them up. Together, these two mechanisms provide long-lasting bronchodilation, improving airflow for individuals with COPD [2].
What is the typical dosage for Anoro Ellipta?
The recommended dosage for Anoro Ellipta is one inhalation once daily [2]. It is crucial to follow the prescribing physician's instructions regarding dosage and administration [4].
What is the difference between Anoro Ellipta and other COPD inhalers?
Anoro Ellipta is a long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA) combination. This dual action targets different pathways to achieve bronchodilation. Many other COPD inhalers may contain only one of these drug classes or combine them with an inhaled corticosteroid, which addresses inflammation [5]. The specific combination in Anoro Ellipta is designed for maintenance treatment of airflow obstruction [2].
Can Anoro Ellipta be used for asthma?
Anoro Ellipta is indicated for the long-term maintenance treatment of airflow obstruction in patients with COPD. It is not approved for the treatment of asthma [2].
What regulatory approvals does Anoro Ellipta have?
Anoro Ellipta has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for the treatment of COPD [2].
What are the potential risks of using umeclidinium/vilanterol?
Potential risks include an increased risk of paradoxical bronchospasm, cardiovascular effects, and exacerbation of narrow-angle glaucoma or urinary retention, especially with anticholinergic medications [4]. Patients with pre-existing conditions should discuss these risks with their doctor [4].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.fda.gov/
[3] https://www.drugpatentwatch.com/
[4] https://www.ema.europa.eu/
[5] https://www.ncbi.nlm.nih.gov/